Santo, V., Mankuzhy, N., Beshiri, K., Celarier, A., Hong, L., Mingo, E. C., Pannu, S., Pecci, F., Garbo, E., Gariazzo, E., Brunetti, L., Aijaz, A., Monaca, F., Chaft, J. E., Corassa, M., Cortellini, A., Vokes, N. I., Aldea, M., Shaverdian, N., Ricciuti, B. (2026). Post-progression treatment strategies and immunotherapy rechallenge sensitivity following chemoradiation and consolidation durvalumab in unresectable stage III NSCLC: The POST-PACIFIC study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8048